A randomized, placebo‐ and sitagliptin‐controlled trial of the safety and efficacy of omarigliptin, a once‐weekly dipeptidyl peptidase‐4 inhibitor, in Japanese patients with type 2 diabetes

AIMS: To assess the safety and efficacy of omarigliptin in Japanese patients with type 2 diabetes (T2D). METHODS: In a 24‐week double‐blind trial, 414 patients with T2D were randomized to omarigliptin 25 mg once weekly, sitagliptin 50 mg once daily or placebo. The double‐blind period was followed by...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Diabetes Obes Metab
Main Authors: Gantz, Ira, Okamoto, Taro, Ito, Yuka, Okuyama, Kotoba, O'Neill, Edward A., Kaufman, Keith D., Engel, Samuel S., Lai, Eseng
Formato: Artigo
Idioma:Inglês
Publicado: Blackwell Publishing Ltd 2017
Assuntos:
Original Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5655696/
https://ncbi.nlm.nih.gov/pubmed/28449368
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.12988
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares